Compare
Rezolute, Inc. vs Milestone Pharmaceuticals Inc. vs Rafael Holdings, Inc. vs Avalo Therapeutics, Inc.
| Latest fiscal year | Rezolute, Inc. RZLT | Milestone Pharmaceuticals Inc. MIST | Rafael Holdings, Inc. RFL | Avalo Therapeutics, Inc. AVTX |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-07-31 | 2025-12-31 |
| Revenue | n/a | n/a | $917.0K | $59.0K |
| Revenue growth (YoY) | n/a | n/a | +44.0% | -86.6% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/m |
| Net margin | n/a | n/a | n/m | n/m |
| Net income | -$77.59M | -$63.06M | -$30.52M | -$78.26M |
| EPS (Diluted) | -$0.75 | -$0.75 | -$1.04 | -$5.84 |
| Operating cash flow | -$64.64M | -$49.04M | -$18.92M | -$51.46M |
| Free cash flow | n/a | -$49.34M | -$18.93M | n/a |
| Cash & equivalents | $10.62M | $73.05M | $52.77M | $15.86M |
| Total assets | $112.85M | $113.56M | $114.11M | $116.46M |
| Total liabilities | $12.16M | $71.79M | $15.74M | $33.41M |
| Shareholders' equity | $100.69M | $41.77M | $98.37M | $83.05M |
| Return on year-end equity | -77.1% | -151.0% | -31.0% | -94.2% |
| Shares outstanding | 96.41M | 106.24M | n/a | 18.51M |
Revenue, most recent five fiscal years
| Fiscal year | Rezolute, Inc. | Milestone Pharmaceuticals Inc. | Rafael Holdings, Inc. | Avalo Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $917.0K Ended 2025-07-31 | $59.0K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $637.0K Ended 2024-07-31 | $441.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $279.0K Ended 2023-07-31 | $1.92M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $410.0K Ended 2022-07-31 | $18.05M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $802.0K Ended 2021-07-31 | $5.40M Ended 2021-12-31 |